Recent Updates
Recently added Catalysts
DNA Positive Sentiment

Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ginkgo Bioworks reported $28 million in third quarter 2026 revenue, down from $29 million a year earlier. The company also signed its first autonomous lab sale with Novo, a top-tier pharmaceutical firm. These results appeared in a press release issued from Boston. The update included a webcast presentation for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ginkgo reported $28 million in revenue for Q3 2026.
  • The company signed its first autonomous lab sale.
  • The sale was made to a top-tier pharma company, Novo.

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. Third Quarter 2026 Financial Results Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year perio

Frequently Asked Questions

What were Ginkgo's Q3 2026 revenues?

Ginkgo reported $28 million in revenue for the third quarter of 2026.

Who bought the first autonomous lab?

The company signed its first autonomous lab sale with Novo, a top-tier pharma firm.

How does Q3 2026 revenue compare?

Revenue fell slightly from $29 million in the prior year period to $28 million.

When did Ginkgo announce results?

Ginkgo announced the results on the date of the press release in Boston.

ShareAdd on Google
Tags: DNA Ginkgo Bioworks Novo autonomous lab Q3 2026
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$302M liquidity · $15M/mo burn
~18 mo
Low dilution risk